U.S. Patent and Trademark Office Issues Patent to CDEX Inc.; Patent Provides System and Method for Detecting a Chemical Substance Using X-Ray Fluorescence.

ROCKVILLE, Md. -- CDEX Inc. (OTCBB:CEXI) announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent number 7,106,826 to CDEX Inc. The patent is a system and method patent for detecting chemical substances using x-ray fluorescence.

Patent Abstract

A system and method for detecting a substance using x-ray fluorescence is disclosed. The detected substances may be explosives or controlled substances that have a specific chemical fluorescent signature. An energy source transmits an x-ray beam at a target. The target may be in a container or under a surface. The beam interacts with the target to produce fluorescent energy. An x-ray detector is at an angle relative to the energy source and gathers the fluorescent energy. The angle differs according to the physical configuration of the system. A portable embodiment will have a different angle than a stationary embodiment. A cooling mechanism cools the x-ray detector. The fluorescent energy is analyzed and processed by a multi-channel analyzer and a computer. The computer determines whether the fluorescent energy from the target matches known fluorescent energies of specific substances. If the substance is detected, appropriate indications are made to prevent damage or acceptance of the substance.

"The issuance of this patent affirms one of our unique approaches to detecting chemical substances that can be applied to explosive trace detection, medication and drug detection, and chemically based suspicious substances," said Jim Griffin CEO of CDEX Inc. "We are very pleased to add this patent to our intellectual property portfolio as it will underpin value creation for the company by allowing us to apply our scientific research to the development of life safety products for the healthcare, security, and brand protection markets."

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market; and (ii) identification of substances of concern (e.g., illegal drugs for law enforcement in the homeland security market) CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.

Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.